Research and application progress of MGMT promoter methylation in gliomas

Chinese Journal of Contemporary Neurology and Neurosurgery

Shi-zhu YU¹  Cui-yun SUN² 

[1] Tianjin Neurological Institute;Department of Neuropathology, Tianjin Medical University General Hospital;

关键词: Glioma;    O (6)⁃methylguanine⁃DNA methyltransferase;    CpG islands;    Methylation;    Review;   

DOI  :  

来源: DOAJ

【 摘 要 】

O⁶-methylguanine-DNA methyltransferase (MGMT) is an important DNArepair enzyme. The promoter methylation status of MGMT gene hasrecently become a biomarker of gliomas. Methylation of the MGMT promoter not only is an important biomarker to evaluate the sensitivity to thechemotherapy with alkylating agents, but also contributes to predictingprognosis and distinguishing between recurrence and pseudoprogression in gliomapatients. Especially in the elderly, MGMT promoter methylation statushas recently been introduced to be a biomarker for glioma classification andpersonalized treatment strategies. This review gives a short summary of thefunction of MGMT and clinical application of MGMT promoter methylationin personalized treatment strategies, prognosis evaluation and differentiationof recurrence and pseudoprogression of glioma.

 

doi: 10.3969/j.issn.1672-6731.2014.07.017

【 授权许可】

Unknown